Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM ...
Lexicon Pharmaceuticals (NASDAQ:LXRX) said the FDA has declined to approve its drug Zynquista, also known as sotagliflozin, as an adjunct to insulin therapy for glycemic control in adults with type 1 ...
Despite winning an FDA approval in 2023 and gaining clarity in May on the regulatory path forward for its Type 1 diabetes prospect sotagliflozin, Lexicon Pharmaceuticals hasn’t had an easy go of it in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results